Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28140979 | 0.84 | POLB (0.50) | FFAR3POLBHDAC3HDAC1HDAC2 | |
| SCHEMBL9637052 | 0.76 | — | — | |
| SCHEMBL6644933 | 0.70 | — | — | |
| Propionic Acid SCHEMBL31533198 | 0.68 | TDP1 (0.77) | FFAR3TDP1HDAC3HDAC1HDAC2 | |
| Hydrogen Peroxide SCHEMBL3473511 | 0.67 | — | — | |
| SCHEMBL27355780 | 0.67 | TDP1 (0.53) | FFAR3TDP1HSD11B1POLBALDH1A1 | |
| SCHEMBL9637101 | 0.66 | — | — | |
| Bicarbonate SCHEMBL261367 | 0.65 | TDP1 (0.83) | FFAR3TDP1HSD11B1HDAC3HDAC1 | |
| Propionic Acid SCHEMBL19409 | 0.64 | FFAR3 (1.00) | FFAR3TDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL42679 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687301-B1 | THIAEPOTHILONE FOR TREATING CANCEROUS DISEASES | LEIBNIZ INST FUER PFLANZENBIOC (DE) | 2009-05-13 | — | — | EP | claimed |
| US-7381743-B2 | Macrocycles for the treatment of cancer | LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) | 2008-06-03 | — | — | US | disclosed |
| US-20070105905-A1 | Novel macrocycles for the treatment of cancer | LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105905-A1 | Novel macrocycles for the treatment of cancer | HCCS, FOLR1, AURKAIP1 | FFAR3 3736/4885TDP1 3923/4885HSD11B1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.